A novel series of pyrrolidine heterocycles was prepared and found to show potent inhibitory activity of CCR1 binding and CCL3 mediated chemotaxis of a CCR1-expressing cell line. A potent, optimized triazole lead from this series was found to have acceptable pharmacokinetics and microsomal stability in rat and is suitable for further optimization and development.
![tert-butyl (2R)-2-[4-[(4-chlorophenyl)methyl]-1,2,4-triazol-3-yl]pyrrolidine-1-carboxylate Structure](https://image.chemsrc.com/caspic/350/1140495-86-8.png)
![4-[(4-chlorophenyl)methyl]-3-[(2R)-pyrrolidin-2-yl]-1,2,4-triazole Structure](https://image.chemsrc.com/caspic/312/1140495-87-9.png)
![tert-butyl (2R)-2-[(4-chlorophenyl)methylcarbamothioyl]pyrrolidine-1-carboxylate Structure](https://image.chemsrc.com/caspic/388/1140495-85-7.png)
